SCHEMBL351666

SCHEMBL351666

O=C(NC1=CC(=O)C2OC2C1O)c1cnc2ccc(Cl)cc2c1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARK7 Q99497 1/20 0.46
TMPRSS4 Q9NRS4 1/20 0.36
LMNA P02545 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
NUDT1 P36639 1/20 0.33
KCNMA1 Q12791 2/20 0.32
MAPT P10636 1/20 0.32
KDM4E B2RXH2 1/20 0.32
GAA P10253 1/20 0.32
NPC1 O15118 1/20 0.32
HTT P42858 1/20 0.32
RAB9A P51151 1/20 0.32
KDR P35968 1/20 0.32
P2RX1 P51575 1/20 0.32
P2RX4 Q99571 1/20 0.32
P2RX7 Q99572 1/20 0.32
GABRA1 P14867 1/20 0.31
GABRG2 P18507 1/20 0.31
GABRB3 P28472 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16649891 0.84 PARK7 (0.40) PARK7LMNAMEN1KMT2AGABRA1
SCHEMBL665039 0.80 PARK7 (0.50) PARK7TMPRSS4LMNAKCNMA1MAPT
SCHEMBL666185 0.80 P2RX1 (0.51) PARK7TMPRSS4MEN1KMT2AKCNMA1
SCHEMBL353155 0.78 PARK7 (0.48) PARK7TMPRSS4KCNMA1NPC1HTT
SCHEMBL665474 0.75 PARK7 (0.49) PARK7TMPRSS4LMNAMEN1KMT2A
SCHEMBL665471 0.73 PARK7 (0.57) PARK7LMNAMEN1KMT2AMAPT
Dehydroxymethylepoxyquinomicin SCHEMBL1671089 0.71 PARK7 (0.54) PARK7LMNAMEN1KMT2AKCNMA1
Dehydroxymethylepoxyquinomicin SCHEMBL14491796 0.71 PARK7 (0.54) PARK7LMNAMEN1KMT2AKCNMA1
SCHEMBL666087 0.70 PARK7 (0.64) PARK7LMNAMEN1KMT2AMAPT
SCHEMBL115782 0.70 PARK7 (0.51) PARK7LMNAMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411376-B1 INHIBITORS OF NF-KB PROFECTUS BIOSCIENCES INC (US) 2015-04-22 EP claimed
US-8629164-B2 Inhibitors of NF-κB PROFECTUS BIOSCIENCES, INC. (US) 2014-01-14 US claimed
US-20120015952-A1 Inhibitors of NF-KB PROFECTUS BIOSCIENCES, INC. (US) 2012-01-19 US claimed
EP-2411376-B1 INHIBITORS OF NF-KB PROFECTUS BIOSCIENCES INC (US) 2015-04-22 EP disclosed
US-8629164-B2 Inhibitors of NF-κB PROFECTUS BIOSCIENCES, INC. (US) 2014-01-14 US disclosed
US-20120015952-A1 Inhibitors of NF-KB PROFECTUS BIOSCIENCES, INC. (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015952-A1 Inhibitors of NF-KB NFKBIA, IKBKB, IKBKG PARK7 3327/4885TMPRSS4 2928/4885LMNA 3191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.